TSN: The Stock Network

⚡ | Fresh stock education to empower investors
🎯 | Daily stock news + CEO interviews
📈 | Join +300k investors & growing 👇
☝️ | Never financial advice

[TSN: The Stock Network @TheStockNet]

EBR Systems, Inc. (ASX:EBR) has announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has initiated a National Coverage Determination process for its WiSE® System.

🫀 The milestone follows EBR’s engagement with CMS through the Transitional Coverage for Emerging Technologies (TCET) pathway
🩺 Represents the most tangible step to date towards establishing national Medicare coverage for WiSE
🧬 WiSE is the first technology to gain entry to CMS’s TCET program, underscoring the differentiated clinical significance of leadless left ventricular endocardial pacing
🚀 CMS review officially commenced on 3 June 2026
⚕️ Final NCD decision expected by March 2027, significantly faster than the typical pathway of more than five years without TCET
🏥 More than 39 hospital contracts secured to date, as well as numerous regional and national contracts with major hospital systems
🔬 Positive NCD decision would establish a uniform national Medicare coverage framework and support expanded patient access

ASX announcement ⚡ https://t.co/z36mq7n5TZ @EBRSystemsInc $EBR

[TSN: The Stock Network @TheStockNet]

What is Australia’s biggest listed company? Look no further than global mining giant, BHP (ASX:BHP), now valued at more than $322 billion after recently overtaking Commonwealth Bank (ASX:CBA). Australia’s biggest bank CBA fell from the top spot but still has a value of more than $272 billion.

BHP’s winning run has been on the back of copper overtaking iron ore as its largest driver of earnings and its now the world’s largest copper producer, making up 51% of the company’s profits. Copper prices remain a key driver of BHP’s growth and have risen strongly over the past year. This demand has been driven by growing electrification, AI and data centres, and concerns about limited mine supply.

#mining #copper #stocks #fintok #money

[TSN: The Stock Network @TheStockNet]

Micro-X (ASX:MX1) has commenced its multi-centre Head CT pilot study, achieving a world-first milestone with human images captured using its carbon nanotube (CNT) Cone Beam CT technology.

🧠 Human imaging milestone: Micro-X has successfully captured its first human Head CT images using its curved array CNT Cone Beam CT scanner, marking a significant technical milestone for the program.
🏥 Clinical study underway: The pilot study will evaluate image quality against conventional CT scans across 108 patients with stroke, brain tumours, intracranial haemorrhage and related conditions.
💰 Funding milestone achieved: Completion of a second Head CT test bench for the Royal Adelaide Hospital triggers a $0.4 million payment to Micro-X under its Medical Research Future Fund program.

“This milestone represents four years of relentless innovation, belief and determination from our team. Achieving first human imaging represents a significant technical milestone for the Company and for cold cathode emitter technology.” - Anthony Skeats, Micro-X Chief Operating Officer

ASX announcement ⚡ https://t.co/SZJjaMFbau

[TSN: The Stock Network @TheStockNet]

Alpha HPA (ASX:A4N) is an Australian specialty materials company supplying high-purity aluminium materials used in semiconductors, EV batteries, AI data centres and advanced manufacturing. With Stage Two of its HPA First Facility progressing in Gladstone, Queensland, Alpha is developing what is expected to become the world’s largest single-site high-purity aluminium facility. Alpha HPA Managing Director Rob Williamson joins @LelSmits from The Stock Network to discuss Australia’s growing role in critical materials, advanced manufacturing and the next phase of growth for Alpha HPA.

🤖 Powering AI, semiconductors and EV supply chains
🇦🇺 Building Australia’s role in future manufacturing
🏭 Scaling production and commercial momentum

Watch the full interview ⚡https://t.co/91TMXTtLaq @Alpha_HPA #A4N

[TSN: The Stock Network @TheStockNet]

Vitrafy Life Sciences (ASX:VFY) has entered a partnership with Vitalant Innovation Center to configure its next-generation cryopreservation ecosystem for red blood cell preservation, targeting an urgent industry need as existing cryopreservation technologies approach discontinuation from 2027.

🩸 The partnership aims to address the looming challenge facing blood banks and healthcare providers as legacy technologies used to cryopreserve red blood cells are phased out with no replacement currently available.
🏥 Vitalant Innovation Center is the second-largest blood network in the United States, representing approximately 10% of the blood collection market, operating around 125 collection sites and serving more than 900 hospitals.
📈 Vitrafy Life Sciences believes the opportunity could extend beyond red blood cells into other blood products, with the Company aiming for its cryopreservation ecosystem to become the successor technology across the broader U.S. blood network.

“We see this partnership as the first of several potential civilian blood opportunities that have stemmed from the successful results in the U.S Army platelets study.” - Vitrafy Life Sciences Managing Director and CEO Brent Owens

ASX Announcement ⚡ https://t.co/orNqurjtU4

[TSN: The Stock Network @TheStockNet]

49 Metals (ASX:49M) has reported what it believes could be a significant breakthrough at its Gold Mountain Project in Nevada's prolific Walker Lane Trend. The result represents the highest-grade intercept recorded at Gold Mountain to date, delivering a 227 gram-metre intercept and potentially identifying the first high-grade feeder structure within the broader epithermal gold system. 49 Metals CEO Phil Carter joins The Stock Network's @LelSmits to discuss the significance of the discovery, what it reveals about the broader Gold Mountain system and the key catalysts ahead.

🔎 High-Grade feeder zone discovery
🛘 What the discovery means for Gold Mountain
🪓 Next steps and upcoming catalysts

Watch the full interview ⚡ https://t.co/HlwLDcMi31
ASX announcement ⚡https://t.co/Mdu094UipT @49Metals #49M

[TSN: The Stock Network @TheStockNet]

If you've ever used the AI assistant Claude, you’re already a customer of one of the most valuable private companies on earth and now Claude’s maker, Anthropic, has filed draft paperwork to go public. The filing comes just after @AnthropicAI closed a US $65 billion dollar funding round, valuing the company at almost one trillion US dollars.

Anthropic’s detailed financials aren't public because it was a confidential IPO filing but the AI arms race is moving to Wall Street, and Anthropic clearly wants to be at the front of the pack.

#AI #fintok #anthropic #claude #stocks

[TSN: The Stock Network @TheStockNet]

Metro Mining (ASX:MMI) is building its position as a key supplier to the global aluminium industry through its flagship Bauxite Hills Mine in Cape York, Queensland. With strong reserves, established operations and growing shipment capacity, the company is focused on supplying China’s expanding bauxite market as aluminium demand rises alongside the global energy transition. Ahead of presenting at @miningclub, Metro Mining CEO and Managing Director Simon Wensley joins The Stock Network’s @LelSmits to discuss the company’s long-term growth strategy, operational scale and outlook for global bauxite demand.

🛡️ Growing demand for aluminium
🪓 Scaling Bauxite Hills operations

Watch the full interview ⚡ https://t.co/6Urd7GrcTG

🗓 Thursday 4 June 2026
🕛 12.15pm
📍 Ivy Ballroom
Register now⚡ https://t.co/tOfghq6mrR @MetroMining $MMI

[TSN: The Stock Network @TheStockNet]

Alligator Energy (ASX:AGE) has delivered strong first field recovery trial results at its Samphire Uranium Project in South Australia, marking a key milestone for its In-Situ Recovery (ISR) development strategy. The first well pattern achieved the company’s 70% uranium recovery target, while flow rates and uranium solution grades exceeded Scoping Study assumptions. Ahead of presenting at the @miningclub, Alligator Energy CEO and Managing Director Andrea Marsland-Smith joins The Stock Network’s @LelSmits to discuss the trial results, ISR performance benchmarks and next steps at Samphire.

🪓 Recovery trial delivers strong ISR benchmarks
⚒️ Next phase of testing underway

Watch the full interview ⚡ https://t.co/rPyvQFwsX8

🗓 Thursday 4 June 2026
🕛 12.15pm
📍 Ivy Ballroom
Register now⚡ https://t.co/tOfghq6mrR @AlligatorEnergy $AGE

[TSN: The Stock Network @TheStockNet]

4DMedical (ASX:4DX) has launched CLEAR, a clinical evidence program designed to fast-track CT:VQ™ entry into the acute pulmonary embolism (PE) market.

🎯 Targeting a total U.S. addressable market of up to US$3B
⚕️ Clinical partnership secured with Mass General Brigham and Massachusetts General Hospital
🫁 CT:VQ™ to be tested head-to-head against current standard-of-care imaging (CTPA)
🔬 Approximately US$2M committed to support the clinical program

"The detection of pulmonary embolism remains a significant problem in emergency medicine. Today, we image too many patients for PE, exposing them to costly and potentially risky contrast, while still missing dangerous clots, contributing to unnecessary death and disease burden." Andreas Fouras, 4DMedical MD/CEO & Founder

ASX announcement ⚡ https://t.co/fbA9fvZe36 @4DMedicalXV #4DX

[TSN: The Stock Network @TheStockNet]

ReNerve Limited (ASX:RNV) has signed an exclusive three-year distribution agreement with Swedish Trading Company (STC), expanding the commercial reach of its NervAlign® nerve repair products across Hong Kong, Macau and the Greater Bay Area, a region with an addressable population of approximately 88 million people.

🌏 The agreement covers Hong Kong, Macau and the Greater Bay Area, providing ReNerve access to one of Asia’s largest and fastest-growing healthcare markets with a combined population of around 88 million people.

🏥 STC brings an established network of hospitals, surgeons and clinical partners across the region, with responsibility for the importation, warehousing, marketing, sales and distribution of ReNerve products.

📈 Initial stocking orders are already being shipped, with the exclusive agreement structured over an initial three-year term including performance milestones and renewal options.

ReNerve CEO and Managing Director Dr Julian Chick commented:

“Securing a distribution partner of STC's calibre is a significant milestone for ReNerve and a direct result of the expanded regulatory approval we recently received across the region. STC has deep relationships with key clinical networks and hospital systems across the region, and we believe they are the ideal partner to drive rapid and effective market penetration for ReNerve.

The partnership follows ReNerve’s recently announced expansion of product approvals across the region and is expected to support broader commercialisation of the Company’s NervAlign® product range.

ReNerve is developing a portfolio of peripheral nerve repair products, led by its FDA-cleared NervAlign® Nerve Cuff, which is designed to improve outcomes for patients undergoing nerve surgery.”

ASX Announcement link ⚡
https://t.co/ywaacyGAU4

[TSN: The Stock Network @TheStockNet]

SpaceX just filed its IPO paperwork with the US government and buried in the filing is a very interesting detail. The SpaceX board says it will grant 1 billion performance-based shares to Elon Musk if certain conditions are met.

One of the conditions is that the company achieves its valuation milestones, but on top of that SpaceX also has to establish a one-million-person colony on Mars. Could this science fiction become a reality?

#SpaceX #ElonMusk #FinTok #IPO #SPCX

[TSN: The Stock Network @TheStockNet]

4DMedical (ASX:4DX) has announced a major strategic move into Europe through the acquisition of Austrian medical imaging AI company @contextflow_rad.

🌍 Immediate commercial and clinical presence across Europe
🫁 Expansion of lung cancer screening and advanced thoracic imaging capabilities
🤖 Addition of AI-powered lung nodule detection technology
🇩🇪 Established European customer base and reimbursement contracts in Germany

"4DMedical has expanded into Europe over the weekend. Upon completion of the transaction, we will have a European platform in a healthcare market approximately half the size of the United States, positioning 4DMedical across ANZ, North America and now Europe." Andreas Fouras, 4DMedical MD/CEO & Founder

ASX announcement ⚡ https://t.co/iKZpZntEcx @4DMedicalXV #4DX

[TSN: The Stock Network @TheStockNet]

Actinogen Medical (ASX:ACW) has received positive scientific advice from the European Medicines Agency (EMA) for its Alzheimer’s disease program, aligning closely with earlier guidance from the US Food and Drug Administration (FDA). The development provides the Company with a clearer pathway toward potential marketing approvals in two major global pharmaceutical markets.

🧠 EMA supports Actinogen Medical’s proposed development pathway for Xanamem® (emestedastat), including one additional pivotal phase 3 trial using a 10mg dose versus placebo following positive XanaMIA trial results.

🌍 Guidance from the EMA closely aligns with prior FDA feedback, giving Actinogen regulatory clarity across both Europe and the United States as it advances discussions with potential development and commercialisation partners.

📊 The EMA also supported the broadening of inclusion criteria for future trials to include more patients with moderate Alzheimer’s disease, while confirming the proposed safety database and additional supporting studies required for a future marketing application.

Actinogen Medical CEO and Managing Director Dr Steven Gourlay commented:

“We are pleased with the clear guidance from the EMA that closely conforms with our plans for streamlined development of Xanamem in Alzheimer’s disease, as agreed previously with the FDA. Importantly, the EMA agreed with our approach for only one additional, pivotal trial using a single 10 mg Xanamem dose versus placebo to support a marketing application for Alzheimer’s in the EU.”

ASX Announcement ⚡
https://t.co/1EWsR2GlKR

[TSN: The Stock Network @TheStockNet]

When did you last book a flight through a travel agent - not Google, or the airline directly - but a travel agent? ASX-listed Web Travel Group (ASX:WEB), owner of online travel agent Webjet, is having a rough year with the stock down 45% year to date.

Webjet is facing multiple headwinds at once, as referenced in its FY26 results presentation. Virgin Australia Holdings (ASX:VGN) has just cut its commissions for Webjet so that Virgin can go direct to customers. Webjet’s CEO has quit and the Iran war has pushed up oil prices, disrupting travel plans.

#travel #stocks #fintok #flying #money @Virgin $VGN

[TSN: The Stock Network @TheStockNet]

What has Robinhood Markets Inc (NASDAQ:HOOD) revealed that would have sounded like science fiction five years ago? Two things:

1. The trading app said that users can now connect AI agents directly to their brokerage accounts to monitor markets, execute trades and rebalance portfolios.
2. Robinhood is also offering users an Agentic Credit Card. If you tell it: 'Buy me those sneakers whenever they drop under $200,’ done. The AI can invest and shop for you, all on autopilot.

Is this the future? Perhaps, but Robinhood notes in the fine print that AI agents could also lose money when trading. As with any investment, there are risks involved.

#tech #stocks #trading #investing #AI @RobinhoodApp $HOOD

[TSN: The Stock Network @TheStockNet]

Pengana Private Equity Trust (ASX:PE1) offers investors access to global private equity and private credit through a listed ASX structure. Managed with Grosvenor Capital Management, PE1 targets diversified institutional-quality investments across healthcare, hospitality and global growth sectors. William Dougall, Investment Specialist at Pengana Capital Group, discusses recent portfolio additions and how PE1 balances long-term opportunities with short-term currency impacts.

📊 Market backdrop
📈 Performance and portfolio quality
🏆 Top 10 holdings

Watch the full interview ⚡https://t.co/3MhMMEKrBu @Pengana_Capital #PE1

[TSN: The Stock Network @TheStockNet]

Epiminder (ASX:EPI), a medical device company developing continuous brain monitoring technology for epilepsy, has reached 25 patient enrolments in its DETECT US clinical study. DETECT is a prospective, randomised, controlled study supporting reimbursement for the Minder® System. Around 20 leading US sites are now active, including @MayoClinic, @Harvard, @Stanford, @Yale, @DukeU and @Penn, with enrolment accelerating as activation expands. CEO Rohan Hoare joins @LelSmits from The Stock Network to discuss what this patient enrolment milestone signals for trial execution, how site expansion is translating into recruitment, and the next key inflection points for investors.

🏥 Site expansion translating into enrolment growth
⚕️ Scaling toward critical trial thresholds
🩺 Epiminder signal quality featured in publication
🔬 Epiminder Director alignment

Watch the full interview ⚡ https://t.co/9J08RXe7bl
ASX announcement ⚡ https://t.co/7qC8x87QqQ #epiminder $EPI